VECTUS BIOSYSTEMS LIMITED — Share Issue/Capital Change 2023

Dec 3, 2023

Application for quotation of +securities

==> picture [21 x 22] intentionally omitted <==

Announcement Summary

Entity name

VECTUS BIOSYSTEMS LIMITED

Announcement Type

New announcement

Date of this announcement

Monday December 04, 2023

The +securities to be quoted are: Other

Total number of +securities to be quoted

ASX +security		Number of +securities to
code	Security description	be quoted	Issue date
VBS	ORDINARY FULLY PAID	19,842	04/12/2023

Refer to next page for full details of the announcement

Application for quotation of +securities

1 / 7

Application for quotation of +securities

==> picture [21 x 22] intentionally omitted <==

Part 1 - Entity and announcement details

1.1 Name of entity

VECTUS BIOSYSTEMS LIMITED

We (the entity named above) apply for +quotation of the following +securities and agree to the matters set out in Appendix 2A of the ASX Listing Rules.

1.2 Registered number type

ABN

Registration number 54117526137

1.3 ASX issuer code

VBS

1.4 The announcement is

==> picture [8 x 8] intentionally omitted <==

New announcement

1.5 Date of this announcement

4/12/2023

Application for quotation of +securities

2 / 7

Application for quotation of +securities

==> picture [21 x 22] intentionally omitted <==

Part 2 - Type of Issue

2.1 The +securities to be quoted are:

==> picture [8 x 8] intentionally omitted <==

Other

2.2 The +securities to be quoted are:

==> picture [8 x 9] intentionally omitted <==

Additional +securities in a class that is already quoted on ASX ("existing class")

2.3c Have these +securities been offered under a +disclosure document or +PDS?

==> picture [8 x 8] intentionally omitted <==

No

2.3d Please provide any further information needed to understand the circumstances in which you are applying to have these +securities quoted on ASX, including why the issue of the +securities has not been previously announced to the market in an Appendix 3B

The issue of 19,842 fully paid ordinary shares to Chief Executive Officer (CEO) and Executive Director Dr Karen Duggan in satisfaction of amounts owing to her as a bonus under her employment contract for her services as CEO and Executive Director for the year ended 31 December 2022, as set out in the Notice of 2023 Annual General Meeting lodged with ASX on 17 October 2023.

2.4 Any on-sale of the +securities to be quoted within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:

==> picture [8 x 8] intentionally omitted <==

The publication of a cleansing notice under section 708A(5), 708AA(2)(f), 1012DA(5) or 1012DAA(2)(f)

Application for quotation of +securities

3 / 7

Application for quotation of +securities

==> picture [21 x 22] intentionally omitted <==

Part 3B - number and type of +securities to be quoted (existing class) where issue has not previously been notified to ASX in an

Appendix 3B

Additional +securities to be quoted in an existing class

ASX +security code and description

VBS : ORDINARY FULLY PAID

Issue date

4/12/2023

Will the +securities to be quoted rank equally in all respects from their issue date with the existing issued +securities in that class? Yes

Issue details

Number of +securities to be quoted

19,842

Are the +securities being issued for a cash consideration?

==> picture [9 x 9] intentionally omitted <==

No

Please describe the consideration being provided for the +securities

The Shares will be issued for nil cash consideration, but in satisfaction of the Company's obligation to pay Dr Duggan¿s bonus under her employment contract for the year ended 31 December 2022.

Please provide an estimate (in AUD) of the value of the consideration being provided per +security for the +securities to be quoted

15,874.000000

Any other information the entity wishes to provide about the +securities to be quoted

19,842 Shares issued to Dr Duggan, based on a bonus of $15,874 payable in shares at $0.80 per share. This is the share price of the December 2022 Placement and Share Purchase Plan, and compares to the share price high and low of $0.67 and $0.44 in March 2023 (when the Board resolved to pay the bonus to Dr Duggan).

The purpose(s) for which the entity is issuing the securities

To pay for services rendered

Please provide additional details

The Shares are being issued in payment of Dr Duggan¿s bonus under her employment contract for her services as CEO and Executive Director for the year ended 31 December 2022.

Application for quotation of +securities

4 / 7

Application for quotation of +securities

==> picture [21 x 22] intentionally omitted <==

==> picture [540 x 710] intentionally omitted <==

Application for quotation of +securities

5 / 7

Application for quotation of +securities

Part 4 - Issued capital following quotation

==> picture [21 x 22] intentionally omitted <==

Following the quotation of the +securities the subject of this application, the issued capital of the entity will comprise:

(A discrepancy in these figures compared to your own may be due to a matter of timing if there is more than one application for quotation/issuance currently with ASX for processing.)

4.1 Quoted +securities (total number of each +class of +securities quoted on ASX following the +quotation of the +securities subject of this application)

	Total number of
ASX +security code and description	+securities on issue
VBS : ORDINARY FULLY PAID	53,209,361
4.2 Unquoted +securities (total number of each +class of +securities issued but not quoted on ASX)
	Total number of
ASX +security code and description	+securities on issue
VBSAI : OPTION EXPIRING 15-MAR-2027 EX NIL	3,480
VBSAH : OPTION EXPIRING 23-NOV-2026 EX NIL	316,000
VBSAJ : OPTION EXPIRING 11-JUL-2027 EX NIL	53,375

4.2 Unquoted +securities (total number of each +class of +securities issued but not quoted on ASX)

Application for quotation of +securities

6 / 7

Application for quotation of +securities

==> picture [21 x 22] intentionally omitted <==

Part 5 - Other Listing Rule requirements

5.1 Are the +securities being issued under an exception in Listing Rule 7.2 and therefore the issue does not need any security holder approval under Listing Rule 7.1? No

5.2 Has the entity obtained, or is it obtaining, +security holder approval for the issue under listing rule 7.1? Yes

5.2a Date of meeting or proposed meeting to approve the issue under listing rule 7.1

22/11/2023

Application for quotation of +securities

7 / 7